BOX 3-1

Recommendations 1–4

Recommendation 1:

The biomarker evaluation process should consist of the following three steps:

1a.

Analytical validation: analyses of available evidence on the analytical performance of an assay;

1b.

Qualification: assessment of available evidence on associations between the biomarker and disease states, including data showing effects of interventions on both the biomarker and clinical outcomes; and

1c.

Utilization: contextual analysis based on the specific use proposed and the applicability of available evidence to this use. This includes a determination of whether the validation and qualification conducted provide sufficient support for the use proposed.

Recommendation 2:

2a.

For biomarkers with regulatory impact, the Food and Drug Administration (FDA) should convene expert panels to evaluate biomarkers and biomarker tests.

2b.

Initial evaluation of analytical validation and qualification should be conducted separately from a particular context of use.

2c.

The expert panels should reevaluate analytical validation, qualification, and utilization on a continual and a case-by-case basis.

Recommendation 3:

The FDA should use the same degree of scientific rigor for evaluation of biomarkers across regulatory areas, whether they are proposed for use in the arenas of drugs, medical devices, biologics, or foods and dietary supplements. Congress may need to strengthen FDA authority to accomplish this goal.


Recommendation 4:

The FDA should take into account a nutrient’s or food’s source as well as any modifying effects of the food or supplement that serves as the delivery vehicle and the dietary patterns associated with consumption of the nutrient or food when reviewing health-related label claims and the safety of food and supplements. Congress may need to strengthen FDA authority to accomplish this goal.

data; the committee’s framework explicitly includes such a process, while allowing for timely, reliable, and effective decision making.

The evaluation framework is intended to be applicable across a wide range of biomarker uses, from exploratory uses for which less evidence is required to surrogate endpoint uses for which compelling evidence is required. The framework is meant for, but not limited to, use in research, clinical, product, and claim development in food, drug, and device industries as well as public health settings, and it is intended to function for



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement